Physician profile
Gerry Sertle
NPI 1174780944
$840.38
in general payments reported to CMS, 2019-2025
16 companies · $23.57 in 2025
The $23.57 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $365 · 2023: $356 · 2024: $95.90 · 2025: $23.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $145.40 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $109.39 | 2022-2023 | Invega Trinza, Invega Sustenna |
| Neurocrine Biosciences, INC. | $103.83 | 2022-2024 | Ingrezza |
| Abbvie INC. | $71.99 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.21 | 2022 | |
| Alkermes, INC. | $59.87 | 2022-2024 | Aristada, Vivitrol, Lybalvi |
| Indivior INC. | $57.58 | 2022-2023 | Perseris |
| Axsome Therapeutics, INC. | $47.11 | 2022-2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $38.23 | 2022-2024 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $32.26 | 2023 | Hetlioz, Fanapt |
| Lundbeck LLC | $25.09 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $17.56 | 2023 | Belsomra |
| Almatica Pharma LLC | $17.19 | 2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $16.42 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.09 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $14.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerry Sertle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.